To the Editor:

I read the article by Hajjar et al. with great enthusiasm.1  First, I would like to congratulate the authors for their ambitious study and reasonable conclusions. They concluded that vasopressin improved clinical outcomes better than norepinephrine in vasoplegic shock after cardiac surgery. I would like to discuss the concerns associated with the use of a pure vasoconstrictor after cardiac surgery.

Transient or sustained vasoplegia is not uncommon after cardiac surgery and it is characterized by a fall in systemic vascular resistance (SVR).2  In addition, myocardial stunning or hibernation after cardiac surgery commonly results in reduction of left ventricular ejection fraction.3  Furthermore, preoperative low ejection fraction is one of the most documented predictors for vasoplegia after on-pump cardiac surgery.2  A reduction in SVR may be associated with improvement in cardiac index.4  To maintain systemic blood pressure solely by increasing SVR without augmenting cardiac contractility may prove counterproductive.5  Therefore, our target should be to maintain SVR within normal limits.6  Although the authors mentioned that the cardiac index did not change after vasopressor infusion, in patients with reduced ejection fraction, cardiac index expectedly reduces after pure vasoconstrictor infusion.7  Vasopressin-related myocardial dysfunction does not arise as a result of increase in SVR, but from a direct effect on cardiac contractility.8  In the current study, the majority of patients (53%) had a normal preoperative ejection fraction (greater than 60%). Unlike vasopressin, its receptor antagonist has shown to improve left ventricular systolic function.9,10  An assessment of ejection fraction in vasoplegic syndrome would have been ideal for better interpretation of the results of this study. In patients with preserved ejection fraction, vasopressin may prove superior to norepinephrine, but generalization of this study finding in patients with vasoplegic syndrome and diminished ejection fraction could be debatable.

Competing Interests

The author declares no competing interests.

References

References
1.
Hajjar
LA
,
Vincent
JL
,
Barbosa Gomes Galas
FR
,
Rhodes
A
,
Landoni
G
,
Osawa
EA
,
Melo
RR
,
Sundin
MR
,
Grande
SM
,
Gaiotto
FA
,
Pomerantzeff
PM
,
Dallan
LO
,
Franco
RA
,
Nakamura
RE
,
Lisboa
LA
,
de Almeida
JP
,
Gerent
AM
,
Souza
DH
,
Gaiane
MA
,
Fukushima
JT
,
Park
CL
,
Zambolim
C
,
Rocha Ferreira
GS
,
Strabelli
TM
,
Fernandes
FL
,
Camara
L
,
Zeferino
S
,
Santos
VG
,
Piccioni
MA
,
Jatene
FB
,
Costa Auler
JO
Jr
,
Filho
RK
:
Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial.
Anesthesiology
2017
;
126
:
85
93
2.
Argenziano
M
,
Chen
JM
,
Choudhri
AF
,
Cullinane
S
,
Garfein
E
,
Weinberg
AD
,
Smith
CR
Jr
,
Rose
EA
,
Landry
DW
,
Oz
MC
:
Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent.
J Thorac Cardiovasc Surg
1998
;
116
:
973
80
3.
Appleyard
RF
,
Cohn
LH
:
Myocardial stunning and reperfusion injury in cardiac surgery.
J Card Surg
1993
;
8
(
2 Suppl
):
316
24
4.
Bixler
TJ
,
Gardner
TJ
,
Donahoo
JS
,
Brawley
RK
,
Potter
A
,
Gott
VL
:
Improved myocardial performance in postoperative cardiac surgical patients with sodium nitroprusside.
Ann Thorac Surg
1978
;
25
:
444
8
5.
Ertmer
C
,
Morelli
A
,
Bone
HG
,
Stubbe
HD
,
Schepers
R
,
Van Aken
H
,
Lange
M
,
Bröking
K
,
Lücke
M
,
Traber
DL
,
Westphal
M
:
Dobutamine reverses the vasopressin-associated impairment in cardiac index and systemic oxygen supply in ovine endotoxemia.
Crit Care
2006
;
10
:
R144
6.
Klinzing
S
,
Simon
M
,
Reinhart
K
,
Bredle
DL
,
Meier-Hellmann
A
:
High-dose vasopressin is not superior to norepinephrine in septic shock.
Crit Care Med
2003
;
31
:
2646
50
7.
Dünser
MW
,
Hasibeder
WR
:
Vasopressin in vasodilatory shock: Ensure organ blood flow, but take care of the heart!
Crit Care
2006
;
10
:
172
8.
Asfar
P
,
Radermacher
P
:
Vasopressin and ischaemic heart disease: More than coronary vasoconstriction?
Crit Care
2009
;
13
:
169
9.
Suzuki
S
,
Yoshihisa
A
,
Yamaki
T
,
Sugimoto
K
,
Kunii
H
,
Nakazato
K
,
Abe
Y
,
Saito
T
,
Ohwada
T
,
Suzuki
H
,
Saitoh
S
,
Kubota
I
,
Takeishi
Y
;
AVCMA investigators
:
Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
Int Heart J
2015
;
56
:
213
8
10.
Yamazaki
T
,
Izumi
Y
,
Nakamura
Y
,
Yamashita
N
,
Fujiki
H
,
Osada-Oka
M
,
Shiota
M
,
Hanatani
A
,
Shimada
K
,
Iwao
H
,
Yoshiyama
M
:
Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
Circ Heart Fail
2012
;
5
:
794
802